Ibrance 125 mg Alternative – Palker (Palbociclib) 125 mg Capsule | Beacon Pharmaceuticals
Palker 125 mg (Palbociclib) Capsule by Beacon Pharmaceuticals. Reference brand: Ibrance. CDK4/6 inhibitor; used in selected HR-positive, HER2-negative breast cancer. Prescription medicine. Brand comparison does not establish interchangeability.
Product Overview
Palker 125 mg Capsule is listed in the supplied Beacon Pharmaceuticals anti-cancer and hematology price list. The stated active ingredient is Palbociclib. Ibrance is a reference brand for the generic ingredient. This is a product-identification comparison, not a claim of verified bioequivalence or interchangeability.
Palker vs Ibrance – Reference Brand Comparison
Ibrance is a recognized reference brand associated with Palbociclib. Palker is listed under Beacon Pharmaceuticals. Their excipients, marketing authorizations, formulation details and regulatory evidence may differ. A clinician or pharmacist must confirm whether substitution is appropriate.
Composition and Active Ingredient
Brand: Palker. Active ingredient: Palbociclib. Strength: 125 mg. Dosage form: Capsule. Therapeutic class: CDK4/6 inhibitor. Listed manufacturer: Beacon Pharmaceuticals Ltd., Bangladesh. Packaging details should be confirmed on the manufacturer’s current pack.
Therapeutic Uses and Indications
Palbociclib is used in selected HR-positive, HER2-negative breast cancer. These are generic-level clinical contexts and do not independently confirm every indication for this particular branded presentation. Eligibility may depend on biomarkers, previous therapy and country-specific labeling.
Mechanism of Action – How Palbociclib Works
Palbociclib inhibits CDK4 and CDK6. This mechanism alone does not establish suitability or effectiveness for an individual patient.
Dosage and Administration
The 125 mg shown is the strength of this capsule, not a recommended daily dose. Dose, timing, food instructions and treatment duration must be determined by the treating specialist using the current authorized prescribing information. Do not change dose or substitute brands or strengths without medical approval.
Contraindications
Contraindications depend on Palbociclib, formulation and individual medical conditions. Review the current official prescribing information, particularly hypersensitivity, pregnancy-related and organ-function restrictions.
Warnings and Precautions
Important safety considerations include neutropenia and infection risk. The prescriber may require laboratory testing, cardiac or organ-function assessment, and ongoing monitoring.
Possible Side Effects
Potential adverse effects and serious reactions include neutropenia and infection risk. Other reactions can occur. Consult the product leaflet for the full adverse-effect profile and seek medical care for severe symptoms.
Drug Interactions
Drug interactions may affect treatment effectiveness or toxicity. Inform the treating clinician of all prescriptions, over-the-counter products, herbal supplements and other treatments.
Pregnancy, Fertility and Breastfeeding
Some oncology and hematology medicines can cause fetal harm and require specific contraception or breastfeeding restrictions. Follow the medicine-specific official labeling and specialist advice.
Storage and Handling
Store according to the instructions printed on the actual Beacon Pharmaceuticals pack. Protect from inappropriate heat, humidity and light, and keep out of reach of children. Do not assume the storage conditions of another brand apply.
Why Is Palker Listed as an Alternative to Ibrance?
The comparison helps identify another listed brand containing Palbociclib. It does not establish identical formulation, regulatory approval, bioequivalence or permission to substitute.
Manufacturer Information
Listed brand: Palker. Manufacturer: Beacon Pharmaceuticals Ltd., Bangladesh. Reference brand: Ibrance. Generic: Palbociclib. Strength: 125 mg. Dosage form: Capsule.
Frequently Asked Questions
What is Palker 125 mg? It is a capsule containing Palbociclib 125 mg according to the supplied Beacon price list. What is it used for? Palbociclib is used in selected HR-positive, HER2-negative breast cancer, subject to specialist assessment. Can it replace Ibrance? Not automatically; a qualified professional must check product-specific equivalence and regulatory requirements. Is a prescription required? Yes, appropriate prescription and specialist supervision are necessary.
Important Medical Disclaimer
This listing is for educational pharmaceutical identification only and is not a substitute for medical advice, official product labeling or regulatory review. Brand, strength and pack details should be confirmed against the current manufacturer information before dispensing.
| Generic Name | Palbociclib |
|---|---|
| Strength | 125 mg |
| Manufacturer | Beacon Pharmaceuticals Ltd. |
Related products
Arimidex 1 mg Alternative – Anastrol (Anastrozole) 1 mg Tablet | Beacon Pharmaceuticals
Ibrance 125 mg Alternative – Palbocent (Palbociclib) 125 mg Capsule | Incepta Pharmaceuticals
Palbocent 125 mg (Palbociclib) Capsule is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Ibrance (Pfizer).
Pack: 21 capsules. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Kisqali 200 mg Alternative – Riboxen (Ribociclib) 200 mg Tablet | Everest Pharmaceuticals
Riboxen 200 mg (Ribociclib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Kisqali (Novartis). It belongs to the CDK4/6 inhibitor class and is used in selected HR-positive, HER2-negative breast cancer regimens.
Active ingredient: Ribociclib
Strength: 200 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Nolvadex 20 mg Alternative – Tamoxi (Tamoxifen) 20 mg Tablet | Beacon Pharmaceuticals
Piqray 150 mg Alternative – Alpesib (Alpelisib) 150 mg Tablet | Everest Pharmaceuticals
Alpesib 150 mg (Alpelisib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Piqray (Novartis). It belongs to the PI3K-alpha inhibitor class and is used in selected PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer regimens.
Active ingredient: Alpelisib
Strength: 150 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Talzenna 1 mg Alternative – Talaparib (Talazoparib) 1 mg Capsule | Everest Pharmaceuticals
Talaparib 1 mg (Talazoparib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Talzenna (Pfizer). It belongs to the PARP inhibitor class and is used in selected genetically defined breast and prostate cancer treatment settings.
Active ingredient: Talazoparib
Strength: 1 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Tykerb / Tyverb 250 mg Alternative – Lapacent (Lapatinib) 250 mg Tablet | Incepta Pharmaceuticals
Lapacent 250 mg (Lapatinib) Tablet is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Tykerb / Tyverb (Novartis).
Pack: 12 tablets. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.

Reviews
There are no reviews yet.